Survey How are the Trump tariffs affecting you? Take our survey and let us know. Milan - Delayed Quote • EUR Pfizer Inc. (1PFE.MI) Follow Add holdings 20.05 +0.38 +(1.91%) At close: April 24 at 5:35:13 PM GMT+2 All News Press Releases SEC Filings Sector Update: Health Care Stocks Rise Late Afternoon Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index rising 1.3% Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to: Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies. Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate Pfizer (NYSE:PFE) Collaborates With Guardant Health on Oncology; Declares US$0.43 Dividend Pfizer (NYSE:PFE) recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its oncology portfolio through advanced liquid biopsy technology. Simultaneously, the company maintained its strong commitment to shareholders by declaring a quarterly dividend. Pfizer's share price saw a modest increase of 1.59% over the past week, aligning with the broader market trend but slightly underperforming the 2.3% market surge. While these company-specific events... PFE vs. LLY: Which Stock Should Value Investors Buy Now? PFE vs. LLY: Which Stock Is the Better Value Option? Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Are Investors Undervaluing Pfizer (PFE) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025. With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the... Stocks That Pay Almost 10% Dividend Yields: Dow and Lyondell Chemicals firms Dow and LyondellBasell are the biggest dividend payers in the S&P 500. Other fat divided payouts include Pfizer, Franklin Resources, and Invesco. Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025. 2 No-Brainer Stocks to Buy With Less Than $30 Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns. Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y). Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know In the closing of the recent trading day, Pfizer (PFE) stood at $22.36, denoting a -0.78% change from the preceding trading day. Pfizer Declares Second-Quarter 2025 Dividend NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer. Why Is Summit Therapeutics Stock Soaring On Wednesday? Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer’s key tumor areas, including breast, genitourinary, Why vaccine makers aren't worried about Trump administration cuts Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting. 3 of Wall Street’s Favorite Stocks Walking a Fine Line Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts. 2 High-Yield Dividend Stocks to Buy for Passive Income Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks can do the heavy lifting. In today's volatile market, where uncertainty is the only constant, dividend investing has regained its shine. Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy? PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter. What's Next for Pfizer After the Company Pulls Its Weight Loss Drug? The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth. Pfizer (NYSE: PFE) has been one of those companies, with danuglipron being a treatment it was hopeful could eventually come to market as a once-daily pill. Performance Overview Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return 1PFE.MI S&P 500 (^GSPC) YTD -19.70% -6.75% 1-Year -12.48% +8.15% 3-Year -27.22% +28.40%